| Literature DB >> 35438460 |
Masaya Maegaki1, Koji Kawamura1,2, Kentaro Hara1, Rina Hosoda1, Sayaka Suzuki1,2, Yuzuru Hosoda1,2, Ken-Ichi Imadome3, Toru Motokura2, Tetsuya Fukuda4.
Abstract
Chronic active Epstein-Barr virus infection (CAEBV) is a subtype of EBV-associated T/NK cell lymphoproliferative disease and is only curable by allogeneic hematopoietic stem cell transplantation. However, finding a human leukocyte antigen (HLA)-matched donor at a suitable time can sometimes be difficult. We report the case of a 60-year-old woman who received prednisolone (PSL) after being diagnosed with autoimmune hepatitis 3 years earlier. She suddenly developed high fever and impaired liver function. Based on a high EBV DNA load in the peripheral blood, CAEBV was diagnosed. The patient was started on cooling therapy with PSL, cyclosporine, and etoposide, which reduced symptoms. Subsequently, she received HLA-haploidentical stem cell transplantation (haplo-SCT) with reduced-intensity conditioning (fludarabine 25 mg/m2 for 5 days, melphalan 50 mg/m2 for 2 days, and total body irradiation at 2 Gy) and post-transplant cyclophosphamide (PTCy) because she lacked an HLA-matched donor. Liver function was restored, and EBV DNA load in peripheral white blood cells became undetectable. The patient is alive without relapse or severe complications over 1 year after transplantation. To our knowledge, this is the first report of successful haplo-SCT with PTCy for CAEBV. This approach may be an alternative therapeutic option for CAEBV patients lacking an HLA-matched donor.Entities:
Keywords: Chronic active Epstein–Barr virus infection (CAEBV); HLA-haploidentical stem cell transplantation (haplo-SCT); Post-transplant cyclophosphamide (PTCy)
Mesh:
Substances:
Year: 2022 PMID: 35438460 DOI: 10.1007/s12185-022-03345-5
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.319